HeliotridineCAS# 520-63-8 |
2D Structure
- Retronecine
Catalog No.:BCN2034
CAS No.:480-85-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 520-63-8 | SDF | Download SDF |
PubChem ID | 442736 | Appearance | Powder |
Formula | C8H13NO2 | M.Wt | 155.2 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (1S,8R)-7-(hydroxymethyl)-2,3,5,8-tetrahydro-1H-pyrrolizin-1-ol | ||
SMILES | C1CN2CC=C(C2C1O)CO | ||
Standard InChIKey | HJSJELVDQOXCHO-JGVFFNPUSA-N | ||
Standard InChI | InChI=1S/C8H13NO2/c10-5-6-1-3-9-4-2-7(11)8(6)9/h1,7-8,10-11H,2-5H2/t7-,8+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Heliotridine Dilution Calculator
Heliotridine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 6.4433 mL | 32.2165 mL | 64.433 mL | 128.866 mL | 161.0825 mL |
5 mM | 1.2887 mL | 6.4433 mL | 12.8866 mL | 25.7732 mL | 32.2165 mL |
10 mM | 0.6443 mL | 3.2216 mL | 6.4433 mL | 12.8866 mL | 16.1082 mL |
50 mM | 0.1289 mL | 0.6443 mL | 1.2887 mL | 2.5773 mL | 3.2216 mL |
100 mM | 0.0644 mL | 0.3222 mL | 0.6443 mL | 1.2887 mL | 1.6108 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Erucifolin N-oxide
Catalog No.:BCN8928
CAS No.:123864-94-8
- 19-O-beta-D-carboxyglucopyranosyl-12-O-beta-D-glucopyranosyl-11,16-dihydroxyabieta-8,11,13-triene
Catalog No.:BCN8926
CAS No.:1011714-20-7
- Nardoaristolone B
Catalog No.:BCN8925
CAS No.:1422517-82-5
- (3R,5S,E)-1,7-Diphenylhept-1-ene-3,5-diol
Catalog No.:BCN8924
CAS No.:232261-31-3
- (3S,5S,E)-1,7-Diphenylhept-1-ene-3,5-diol
Catalog No.:BCN8923
CAS No.:87095-75-8
- 5-Hydroxy-7,8-dimethoxy (2R)-flavanone-5-O-beta-D-glucopyranoside
Catalog No.:BCN8922
CAS No.:942626-74-6
- (1E)-3-methoxy-8,12-epoxygermacra-1,7,10,11-tetraen-6-one
Catalog No.:BCN8921
CAS No.:1393342-06-7
- Ginsenoside MC
Catalog No.:BCN8920
CAS No.:175484-06-7
- 3-Hydroxy-4',5-dimethoxystilbene
Catalog No.:BCN8919
CAS No.:58436-29-6
- Isoeuphorbetin
Catalog No.:BCN8918
CAS No.:50677-55-9
- Licoflavanone
Catalog No.:BCN8917
CAS No.:119240-82-3
- Schisphenin E
Catalog No.:BCN8916
CAS No.:1311376-52-9
- Integerrimine N-oxide
Catalog No.:BCN8930
CAS No.:85955-28-8
- Intermedine N-oxide
Catalog No.:BCN8931
CAS No.:95462-14-9
- Jacobine N-oxide
Catalog No.:BCN8932
CAS No.:38710-25-7
- Merenskine
Catalog No.:BCN8933
CAS No.:96657-94-2
- Merenskine N-oxide
Catalog No.:BCN8934
CAS No.:96657-95-3
- 7-O-Acetyllycopsamine N-oxide
Catalog No.:BCN8935
CAS No.:685132-58-5
- Riddelline N-oxide
Catalog No.:BCN8936
CAS No.:75056-11-0
- Senecivernine N-oxide
Catalog No.:BCN8937
CAS No.:101687-28-9
- Sceleratine N-oxide
Catalog No.:BCN8938
CAS No.:103184-92-5
- Glucohesperin
Catalog No.:BCN8939
CAS No.:33049-17-1
- 6-Hydroxytropinone
Catalog No.:BCN8940
CAS No.:5932-53-6
- Glucoraphenin
Catalog No.:BCN8942
CAS No.:108844-81-1
Potentially toxic pyrrolizidine alkaloids in Eupatorium perfoliatum and three related species. Implications for herbal use as boneset.[Pubmed:29968391]
Phytochem Anal. 2018 Nov;29(6):613-626.
INTRODUCTION: Pro-toxic dehydropyrrolizidine alkaloids are associated with liver disease in humans. The potential for long-term, low-level or intermittent exposures to cause or contribute to chronically-developing diseases is of international concern. Eupatorium perfoliatum is a medicinal herb referred to as boneset. While the presence of dehydropyrrolizidine alkaloids in some Eupatorium species is well-established, reports on Eupatorium perfoliatum are scant and contradictory. OBJECTIVE: To investigate the presence of dehydropyrrolizidine alkaloids in a survey of boneset samples and related alcoholic tinctures, and hot water infusions and decoctions. METHODS: Methanol, hot water or aqueous ethanol extracts of Eupatorium perfoliatum and three closely-related species were subjected to HPLC-ESI(+)MS and MS/MS analysis using three complementary column methods. Dehydropyrrolizidine alkaloids were identified from their MS data and comparison with standards. RESULTS: Forty-nine samples of Eupatorium perfoliatum were shown to contain dehydropyrrolizidine alkaloids (0.0002-0.07% w/w), the majority dominated by lycopsamine and intermedine, their N-oxides and acetylated derivatives. Alcoholic tinctures and hot water infusions and decoctions had high concentrations of the alkaloids. Different chemotypes, hybridisation or contamination of some Eupatorium perfoliatum samples with related species were suggested by the co-presence of retronecine- and Heliotridine-based alkaloids. CONCLUSIONS: Sampling issues, low and high alkaloid chemotypes of Eupatorium perfoliatum or interspecies hybridization could cause the wide variation in dehydropyrrolizidine alkaloid concentrations or the different profiles observed. Concerns associated with dehydropyrrolizidine alkaloids provide a compelling reason for preclusive caution until further research can better define the toxicity and carcinogenicity of the dehydropyrrolizidine alkaloid content of Eupatorium perfoliatum. [Correction added on 12 July 2018, after first online publication: The 'Conclusions' section in the abstract has been added.].
PXR: Structure-specific activation by hepatotoxic pyrrolizidine alkaloids.[Pubmed:29665350]
Chem Biol Interact. 2018 May 25;288:38-48.
Pyrrolizidine alkaloids (PAs) comprise a large group of more than 660 secondary metabolites found in more than 6000 plant species worldwide. Acute PA intoxication induces severe liver damage. Chronic exposure to sub-lethal doses may cause cumulative damage or cancer. Nuclear receptor activation often constitutes a molecular event for xenobiotic-induced toxicity. However, so far nothing is known about potential interactions of PAs with nuclear receptors as a toxicological mode of action. Thus, in the present study PA-dependent activation of a comprehensive panel of nuclear receptors (PPARs, LXRalpha, RARalpha, RXRalpha, FXR, CAR, PXR, ERalpha/beta) was investigated using GAL4/UAS-based transactivation reporter gene assays. To cover the most frequently occurring PA structure types (retronecine, Heliotridine and otonecine type; as well as monoester, open-chain diester and cyclic diester) different PAs were analyzed for interaction with nuclear receptors. Most of the nuclear receptors investigated were not affected by the tested PAs. However, significant activation was found for PXR, which was exclusively activated by the open-chain diesters, echimidine and lasiocarpine. Induction of the model PXR target gene CYP3A4 by PAs was verified at the mRNA, protein and enzyme activity level. In conclusion, PXR activation and PXR-mediated induction of CYP3A4 expression by PAs seem to be structure-dependent. Data suggest that only open-chain diesters act as PXR agonists. This might imply that a PXR-mediated mode of action may contribute to the hepatotoxicity of PAs that is dependent on PA structure.
Structure-dependent induction of apoptosis by hepatotoxic pyrrolizidine alkaloids in the human hepatoma cell line HepaRG: Single versus repeated exposure.[Pubmed:29458164]
Food Chem Toxicol. 2018 Apr;114:215-226.
Pyrrolizidine alkaloids (PA) are secondary plant compounds. PA intoxication in humans causes severe acute and chronic hepatotoxicity. However, the molecular mechanisms of PA hepatotoxicity in humans are not well understood yet. Therefore, we investigated cell death parameters in human HepaRG cells following either single (24h) or repeated dose treatment (14d) with structurally different PA of the retronecine (echimidine, senecionine), Heliotridine (heliotrine), and otonecine type (senkirkine). After 24h of exposure only retronecine-type PA were cytotoxic in HepaRG cells and induced apoptosis indicated by a loss of membrane asymmetry, disruption of the mitochondrial membrane potential, and increased pro-caspase and PARP cleavage. In contrast, after 14d all four PA exerted the aforementioned effects. Furthermore, the apoptotic events caspase 3, 8 and 9 activation as well as nuclear condensation and DNA fragmentation were only detected for the retronecine-type PA after single exposure (6h). Overall, our studies revealed a time- and structure-dependent apoptosis after PA exposure, suggesting that retronecine-type PA seem to be more potent apoptosis inducers than Heliotridine- or otonecine-type PA. Furthermore, our results suggest that PA-induced apoptosis in HepaRG cells occur most probably by involving both, the extrinsic death receptor pathway as well as the intrinsic mitochondrial pathway.